Nizoral™

ketoconazole

The first oral anti-fungal effective against all pathogenic fungi

dosage:

Vaginal Candidosis:	All other superficial and systemic fungal infections:
1 tablet b.i.d. (with food) for 5 days	1 tablet daily (with food) until complete symptomatic and mycological cure is obtained

PRESCRIBING INFORMATION

Presentation: White, flat, half scored uncoated tablets marked 'JANSSEN' on the reverse. Each contains ketoconazole 200 mg. **Uses:** Nizoral is an orally active antimycotic for the treatment, in adults, of superficial and systemic mycoses including dermatophyte and yeast infection of the skin and hair, yeast infection of the mouth and G I tract, recurrent or chronic vaginal candidosis not responding to topical treatment. Also maintenance treatment in systemic mycosis and chronic mucocutaneous candidosis and prophylaxis in "at risk" patients. In children: systemic mycosis and severe local infection where previous topical treatment has failed. **Side-effects, Precautions, Contra-indications:** Contra-indicated in pregnancy. For optimum absorption, Nizoral should be taken with meals. The use of agents which reduce gastric acidity (anti-cholinergic drugs, antacids, H_2 blockers) should be avoided and, if indicated, such drugs should be taken not less than two hours after Nizoral. Nausea, skin rash, occasionally observed.

Not all indications are as yet approved in all countries.

Janssen Pharmaceutica
Beerse, Belgium

Presentation. Actifed is available as tablets and syrup. Each tablet contains 2.5mg triprolidine hydrochloride and 60mg pseudoephedrine hydrochloride. Each 5ml of syrup contains 1.25mg triprolidine hydrochloride and 30mg pseudoephedrine hydrochloride. **Indications** Symptomatic relief of upper respiratory congestion in the common cold, hay fever, vasomotor and allergic rhinitis, acute sinusitis, otitis barotrauma. **Dosage** Three times a day: Adults and children over 12 years: 1 tablet or 10ml. 6-12 years: 7.5ml. 1-6 years: 5ml. 3-12 months: 2.5ml. **Contra-indications** Actifed is contra-indicated in persons hypersensitive to pseudoephedrine or triprolidine and in those under treatment with MAO inhibitors and within 2 weeks of stopping such treatment. **Precautions** Although at recommended dosage pseudoephedrine has virtually no pressor effects in normotensive subjects, Actifed should be used with caution in patients with cardiovascular disorders. As with other antihistamine containing preparations, drowsiness may occur. In some patients the action of antihistamines may be potentiated by alcohol. 25 tablets. PL3/5003. 150ml. PL3/5004.

Actifed™

Pseudoephedrine Hydrochloride BP
Triprolidine Hydrochloride BP

The decongestant chosen by NASA

Further information is available on request.
Wellcome Medical Division, The Wellcome Foundation Ltd., Crewe, Cheshire

Magnapen

ampicillin/flucloxacillin

Reliable broad-spectrum cover for the patient at risk.

Throughout the management of surgical patients, Magnapen offers:

- Decisive, bactericidal action against relevant pathogens – Strep. viridans,[1] H. influenzae,[2] and virtually all strains of Staph. aureus.[3,4]
- High blood levels and excellent tissue penetration.[5]
- The acknowledged safety of penicillin.
- Oral and parenteral forms – now including 1g vial for added convenience and dosage flexibility.

1. Zbl. Bakt. Hyg. I. Abt. Orig. A., (1976) **236** 235 2. Antibiotic and Chemotherapy (1973) Publ Churchill Livingstone. 4th Edition p 280
3. Brit. med. J. (1978) **2** 536 4. Brit. med. J. (1978) **1** 1679 5. Brit. J. clin. Pharmac. (1978) **6** 135

BRL 2029

Prescribing information

Uses: Severe infections. Post-operative chest and wound infections. Prophylaxis in major surgery.
Usual Adult Dosage: Oral: 500mg-1g q.i.d., ½-1 hour before meals. I.M.: 500mg q.i.d., dissolved in 1.5ml Water for Injections B.P. or 1g q.i.d., dissolved in 2ml Water for Injections B.P. I.V. (Injection): 500mg q.i.d., dissolved in 10ml Water for Injections B.P. or 1g q.i.d., dissolved in 20ml Water for Injections B.P. Administer by slow intravenous injection (3-4 minutes). I.V. (Infusion): Magnapen injection may be added to infusion fluids or injected, suitably diluted, into the drip tube over a period of 3-4 minutes. Magnapen solutions for injection should be used immediately. Magnapen may be added to most intravenous fluids but should not be mixed with blood products or other proteinaceous fluids (e.g. protein hydrolysates). In intravenous solutions containing dextrose or other carbohydrates Magnapen should be infused within 2 hrs.
Usual Children's Dosage: 2-10 years: ½ adult dose. Under 2 years: ¼ adult dose. (Ampiclox Neonatal is recommended for the treatment of neonates and premature babies. PL 0038/5001, 5009.)
Side-effects: As with other penicillins. An erythematous rash may occasionally occur, as with ampicillin. The incidence of this rash is particularly high in patients with infectious mononucleosis. If a rash is reported it is advisable to discontinue treatment.
Contra-indications: Penicillin hypersensitivity; ocular administration.

Availability and Basic NHS Prices
(Correct at February 1981)
CAPSULES 500mg £4.22 for 20
SYRUP 125mg/5ml £3.51 for 100ml. VIALS 500mg 98p each
1g £1.97 each

Favourable Hospital Rates are available from the Company. Further information on Magnapen and a Data Sheet are available on request to the Company.

Magnapen (ampicillin with flucloxacillin in equal parts) is a product of

Beecham Research Laboratories
Brentford, England.
PL 0038/0089, 0090, 0120.



Behind the gentleness of

Burinex* K

bumetanide and slow release potassium chloride

lies the power of

Burinex

Burinex K
gently effective
for maintenance

Burinex tablets
combine strength with
gentleness for more refractory oedema

Burinex injection
fast powerful action for emergencies

Formulations Burinex Injection: 0.5 mg/ml in 2 ml, 4 ml and 10 ml ampoules. Burinex Tablets: 1 mg and 5 mg. Burinex K: 0.5 mg bumetanide, 7.7 mmol slow release potassium chloride. **Indications** Acute pulmonary oedema and oedema of cardiac, renal or hepatic origins. **Dosages** Burinex Injection: Initially 1-2 mg i.v., if necessary repeated at 20 minute intervals to achieve desired response. Where appropriate higher doses may be given by infusion over 30-60 minutes. Burinex Tablets: Most patients require *1 mg Burinex* daily as morning or evening dose. In refractory cases dosage can be increased to achieve the desired response. For high dose treatment *5 mg Burinex* should be given initially and increased by 5 mg steps at 12-24 hour intervals until desired response is achieved. Burinex K: Most patients require 2 tablets Burinex K daily. **Contra-indications, Precautions and Side Effects** Contra-indicated in hepatic coma, severe electrolyte depletion and severe progressive renal failure. Hypokalaemia and circulatory collapse may follow inappropriately excessive diuresis. Concurrent digitalis therapy in association with electrolyte disturbances may lead to digitalis toxicity. Concurrent antihypertensive or antidiabetic therapy may require adjustment. Caution should be exercised in the first trimester of pregnancy. Burinex K is contra-indicated in combination with potassium sparing agents. Burinex K should be stopped immediately if signs or symptoms of bowel ulceration appear. Side effects such as skin rashes, muscular cramps, rises in serum uric acid and thrombocytopenia may rarely occur. **Product Licence Numbers:** Burinex Injection: 0043/0060 Burinex Tablets: 0043/0021, 0043/0043 Burinex K: 0043/0027B **Basic N.H.S. Prices** Burinex Injection: 0.5 mg/ml – 5 x 4 ml £3.34 Burinex Tablets: 1 mg – 100 tabs £4.74 Burinex K: 100 tabs £3.24

*Burinex is a trade mark

LEO

Leo Laboratories Limited, Longwick Road, Princes Risborough, Aylesbury, Bucks. HP17 9RR